Literature DB >> 10836378

Role of porcine P-selectin in complement-dependent adhesion of human leukocytes to porcine endothelial cells.

S A Rollins1, K K Johnson, L Li, C Birks, L A Matis, R P Rother.   

Abstract

BACKGROUND: Rapid leukocyte adherence to donor organ vasculature is a hallmark of hyperacute xenograft rejection. However, the molecular interactions required for leukocyte binding to vascular endothelium have not been characterized. METHODS AND
RESULTS: Binding assays performed between human neutrophils and porcine aortic endothelial cells (PAEC) after exposure to human complement demonstrated that adhesion was mediated by both surface-bound C3b and C5b-9 activity. C5b-9-dependent adhesion was blocked by neuraminidase treatment of the neutrophils, suggesting that this binding was mediated by porcine P-selectin. Porcine P-selectin was isolated from a PAEC cDNA library. The porcine P-selectin primary sequence contained an open reading frame encoding 646 amino acids with 82% identity to human P-selectin. Recombinant soluble porcine P-selectin specifically bound to human neutrophils and HL-60 cells. Transfection of COS cells with the full-length porcine P-selectin cDNA resulted in surface expression of the protein and markedly increased the binding of human neutrophils to these cells. The binding of both soluble and COS-expressed porcine P-selectin to human neutrophils was blocked by pretreatment of the neutrophils with neuraminidase or the addition of EDTA. Finally, treatment of PAEC with human thrombin or normal human serum but not purified human C5a- or C8-deficient human serum resulted in the rapid expression of porcine P-selectin on the cell surface.
CONCLUSIONS: This report establishes that porcine P-selectin supports the binding of human neutrophils to PAEC in vitro. Further, these data suggest that sublytic deposition of C5b-9 during hyperacute rejection results in the expression of porcine P-selectin, which may contribute to the rapid adhesion of neutrophils to porcine xenografts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10836378     DOI: 10.1097/00007890-200004270-00023

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  The role of complement activation in atherogenesis: the first 40 years.

Authors:  Sonia I Vlaicu; Alexandru Tatomir; Violeta Rus; Armugam P Mekala; Petru A Mircea; Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

2.  Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium.

Authors:  I Kourtzelis; A Ferreira; I Mitroulis; D Ricklin; S R Bornstein; C Waskow; J D Lambris; T Chavakis
Journal:  Horm Metab Res       Date:  2014-10-28       Impact factor: 2.936

3.  Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis.

Authors:  Susanna H Weerth; Horea Rus; Moon L Shin; Cedric S Raine
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

4.  Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.

Authors:  M Fung; M Lu; H Fure; W Sun; C Sun; N Y Shi; Y Dou; J Su; X Swanson; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

Review 5.  Platelets influence vascularized organ transplants from start to finish.

Authors:  A D Kirk; C N Morrell; W M Baldwin
Journal:  Am J Transplant       Date:  2008-11-27       Impact factor: 8.086

Review 6.  Complement activation and cardiac surgery: a novel target for improving outcomes.

Authors:  Gregory L Stahl; Stanton K Shernan; Peter K Smith; Jerrold H Levy
Journal:  Anesth Analg       Date:  2012-07-13       Impact factor: 5.108

7.  Molecular cloning and expression analysis of P-selectin from Zebrafish (Danio rerio).

Authors:  Guijin Sun; Jie Pan; Kechun Liu; Xue Wang; Sifeng Wang
Journal:  Int J Mol Sci       Date:  2010-11-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.